Current Opportunities

Akcea Therapeutics Retains The Chase Group to Secure Senior Vice President for Global Medical Affairs

March 26, 2020
Akcea Therapeutics is driven by determination and focus on addressing the unmet needs and complex medical challenges of patients with serious and rare disorders. As… Continue Reading →

A New Decade, A New Partnership, and Continued Growth for Alexza Pharmaceuticals and The Chase Group

March 24, 2020
At the crossroads of innovation and advanced technology, Alexza Pharmaceuticals is working to develop products for the acute treatment of underserved medical needs in neuroscience…. Continue Reading →

Eisai, Inc. Retains The Chase Group to Build US Medical Affairs Leadership Team

February 11, 2020
Eisai, Inc.’s partnership with Merck has proven to be successful with the FDA approval of the Keytruda and Lenvima Combination Treatment. With 13 indications for… Continue Reading →

Akcea Retains The Chase Group to Secure Senior HR Leader for the Company’s Executive Team

February 3, 2020
The Chase Group is excited to reengage partnership with Akcea Therapeutics to recruit the company’s Vice President of Human Resources. The Vice President will lead… Continue Reading →

The Chase Group Drug Safety Expertise Utilized by Ionis Pharmaceuticals

December 20, 2019
As the leading innovator in RNA-targeted therapeutics, Ionis Pharmaceuticals requires world-class scientists and business leaders whose passion to innovate is matched only by their commitment… Continue Reading →

Eisai, Inc. Cuts to the Chase for Their Recruiting Expertise in Global Medical Affairs, Oncology

September 9, 2019
A boutique firm working exclusively in life sciences, The Chase Group, with 25+ years’ executive search experience, can identify and deliver the highest quality executives… Continue Reading →

Through Partnership With The Chase Group, Aeglea BioTherapeutics Continues Building Rare Disease Clinical Development Leadership Team

August 12, 2019
The Chase Group is honored to continue our partnership with Aeglea BioTherapeutics as we work to build their Rare Disease Clinical Development Leadership team. As… Continue Reading →

Aeglea BioTherapeutics (NASDAQ: AGLE) Partners with The Chase Group to Build Clinical Development Team for Rapidly Expanding Genetic Rare Disease Portfolio

November 9, 2018
As a leader in engineering human enzymes to address significant unmet medical needs in rare genetic diseases and cancer, Aeglea BioTherapeutics is committed to using… Continue Reading →

Ionis Pharmaceuticals Continues to Cut to the Chase

July 30, 2018
Ionis Pharmaceuticals continues to partner with The Chase Group to find high caliber talent to join them in revolutionizing medicine through the discovery and development… Continue Reading →

Ipsen US Retains The Chase Group to Recruit a Vice President, Neurology Franchise Head

July 18, 2018
With the relocation of their headquarters to Cambridge, MA, Ipsen US is entering a new era of innovation and growth to become a leading global… Continue Reading →
Copyright © 1993-2025 The Chase Group. All Rights Reserved.